Pharma/Biotech Update: Boehringer Ingelheim Receives FDA Approval for Blood Clots
April 8, 2014; Posted by: WeBleed staff
Boehringer Ingelheim (BI) gets approval from the United States Food and Drug Administration for Pradaxa to treat Deep Vein Thrombosis and Pulmonary Embolism.
In an article from earlier today via FiercePharma, pharmaceutical giant Boehringer Ingelheim’s (BI) drug Pradaxa has recently been given the okay to treat blood clot conditions deep vein thrombosis (DVT) and pulmonary embolism (PE).
“Deep vein thrombosis and pulmonary embolism can be life-threatening,” says Dr. Sabine Luik, Boehringer’s SVP of Medicine and Regulatory Affairs, “Boehringer Ingelheim is pleased that patients will now have a new and efficacious therapeutic option for this complex condition. This approval is a testament to our commitment to evaluate Pradaxa in new areas of cardiovascular treatment, in order to address evolving patient needs.”
This means BI can now throw its hat into the ring to help blood clotting patients. Pradaxa was initially only labeled to treat atrial fibrillation in stroke patients. This addition adds a plethora of people affected by blood clots in some way to have another choice in their treatment. Other competing products, like Xarelto and Eliquis, have had a head start in the blood disorder market. FDA analysis may prove that Pradaxa is not only the popular option but may also be the safest option having the least amount of safety issues and liability claims.
Whenever the term “off label use” of a product is brought up, which is considered illegal when mentioned by the company itself, it makes the public wonder how many pharmaceuticals that are currently on the market could be better off being used for something different. In any case, the approval will come as another choice when considering how to handle a blood clot going forward.
Photo Credit – Boehringer Ingelheim
